search Search
search Search
  1. hcp portal
  2. product information
Product information

Product Information

Explore our comprehensive resources for product details, usage guidelines, and the latest updates in diabetes technology.

Product Characteristics

myLoop represents a therapeutic option for individuals diagnosed with diabetes, combining the YpsoPump insulin pump, the CamAPS FX mobile application, and the compatible Continuous Glucose Monitoring (CGM) systems Dexcom G6 or Abbott FreeStyle Libre 3/ Libre 3 Plus. The CamAPS FX algorithm is designed to run on the user's personal smartphone and the CamAPS FX app has been approved as the only app for use by pregnant women with Type 1 Diabetes and individuals with Type 1 Diabetes from the age of one and older.

Dexcom G7

FreeStyle Libre 3

Abbott FreeStyle Libre 3/Libre 3 Plus

CamAPS FX

YpsoPump

Compatibility lists

Related Content

You may also be interested in ...

bulb
Educational material
Discover recent study data and how myLoop powered by CamAPS FX can make a difference for your patients with T1D.
Discover more
phone
Events
Stay informed. Follow us for the latest insights on the most rapidly evolving areas of diabetes technology and treatments.
Follow us
download
Resources
Explore factsheets, downloads, and scientific publications to support your practice and advance patient care.
Explore more

1. Waldenmaier D. et al. First User Experiences With a Novel Touchscreen-Based Insulin Pump System in Daily Life of Patients With Type 1 Diabetes Experienced in Insulin Pump Therapy. Journal of Diabetes Science and Technology. 2019;13(1):96-102. doi: 10.1177/1932296818785386.2. Dunn TC, et al. Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: A European analysis of over 60 million glucose tests. Diabetes Res Clin Pract. 2018;137:37-46. doi: 10.1016/j.diabres.2017.12.015.

3. Bolinder J, et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016 Nov 5;388(10057):2254-2263. doi: 10.1016/S0140-6736(16)31535-5.

4. Data on File. Abbott Diabetes Care.

5. Barnard K. D. et al.: Closing the Loop in Adults, Children and Adolescents With Suboptimally Controlled Type 1 Diabetes Under Free Living Conditions: A Psychosocial Substudy.J Diabetes Sci Technol. 2017 Nov;11(6):1080-1088. DOI: 10.1177/1932296817702656.

6. Barnard K. D. et al.: Closing the Loop in Adults, Children and Adolescents With Suboptimally Controlled Type 1 Diabetes Under Free Living Conditions: A Psychosocial Substudy.J Diabetes Sci Technol. 2017 Nov;11(6):1080-1088. DOI: 10.1177/1932296817702656.

DisclaimerThe product images are for illustrative purposes only.mylife and YpsoPump are registered trademarks of Ypsomed AG in several countries.CamAPS is a registered trademark of CamDiab Ltd.Dexcom and Dexcom G6 are registered trademarks of Dexcom, Inc. in the United States and/or other countries.The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission.The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of such marks by Ypsomed is under license.Other trademarks are the property of their respective owners.

myLoop with Freestyle Libre3/Libre 3 Plus: The innovations described are available in selected countries and expanding to further countries soon. Expansion is contingent upon local regulatory approval.Insulin pumps and Automated Insulin Delivery (AID) systems can improve glucose management but do not remove the risk of diabetic ketoacidosis (DKA). Because these systems use only rapid-acting insulin, any interruption in insulin delivery (e.g., infusion-set failure, occlusion, empty reservoir, or device malfunction) can rapidly lead to ketosis and DKA, even if glucose levels are not markedly elevated.Healthcare professionals should ensure that users understand the risk of DKA associated with pump and AID therapy, particularly in situations where insulin delivery may be interrupted. Users should be trained to recognise and troubleshoot delivery issues promptly, know when and how to check for ketones and seek urgent medical assistance. Advise to always keep a reliable backup method of insulin delivery available.This information is provided for general educational purposes and is intended for healthcare professionals. It does not replace individual clinical judgement or patient-specific medical advice.

information
For safety information on mentioned products, see

link mylife-diabetescare.com/safety

Ypsomed Ltd.1 Park CourtRiccall RoadEscrickYO19 6EDUnited Kingdom

Free Call 0344 856 7820 (UK)Free Call 1800 911 522 (ROI)F +44 844 507 0443

info@ypsomed.co.uk

Trademarks and images

mylife, YpsoPump, YpsoPod and Orbit are registered trademarks of Ypsomed Diabetes Care AG in several countries. Other trademarks are the property of their respective owners. The product images are for illustrative purposes only.

© 2026 mylife Diabetes Care AG